First in Man Study of Pulsed Field Ablation System for the Treatment of Paroxysmal Atrial Fibrillation in 1 Patient

Exclusion Criteria

• •1. AF secondary to electrolyte imbalance, thyroid disease, or reversible cause;
• •2. AF episodes lasting more than 7 days;
• •3. History of previous AF ablation therapy;
• •4. Previous valve repair, replacement or artificial valve implantation; previous atrial septal defect closure, patent foramen ovale closure cardiac intervention or surgery;
• •5. Any myocardial infarction (MI), coronary artery bypass grafting (CABG) procedure or percutaneous coronary intervention (PCI) during the 3-month interval preceding the consent date;
• •6. Hypertrophic Obstructive Cardiomyopathy (HOCM);
• •7. NYHA class III and IV;
• •8. Presence of implanted ICD, CRT;
• •9. Documented active thrombus in the left atrium or atrial appendage on imaging;
• •10. Any carotid artery stent implantation or endarterectomy within the previous 6 months;
• •11. Severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gas or severe breathing difficulties;
• •12. Known pulmonary vein stenosis
• •13. Contraindication to isoproterenol therapy.
• •14. Anticoagulation contraindications, and history of blood clotting or bleeding abnormalities;
• •15. Patients with acute systemic infection;
• •16. （eGFR）\< 60mL/min/1.73m2, or have a history of kidney dialysis;
• •17. Women who are pregnant and/or breast feeding or unable to use contraception during the trial;
• •18. Enrollment in another clinical trial evaluating other devices or drugs during the same period;
• •19. Life expectancy less than 12 months (such as patients with advanced cancer);
• •20. Abnormalities or diseases that the investigator considers to be excluded from the study's coverage.